VF
EWTX icon

Virtu Financial’s Edgewise Therapeutics EWTX Stock Holding History

Virtu Financial’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-24,037
Closed -$263K – 1602
2023
Q4 		$263K Buy
+24,037
New +$169K 0.02% 664
2023
Q3 		– Sell
-11,010
Closed -$85K – 1476
2023
Q2 		$85K Buy
+11,010
New +$92.9K 0.01% 1070

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Virtu Financial's EWTX Position: Q1 2024 in Review

Virtu Financial sold out of Edgewise Therapeutics (EWTX) in Q1 2024, closing a stake of 24,037 shares — an estimated $263K sold.

Virtu Financial first reported a position in EWTX in Q2 2023 and held it in 2 quarters. The position peaked at $263K in Q4 2023. 129 funds tracked by Wall St. Rank hold EWTX as of Q1 2024.

  • Virtu Financial reported no remaining Edgewise Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Virtu Financial sold 24,037 Edgewise Therapeutics shares in Q1 2024, an estimated $263K.
  • Virtu Financial first reported a position in Edgewise Therapeutics in Q2 2023 and held it in 2 quarters.
  • Virtu Financial's Edgewise Therapeutics position peaked at $263K in Q4 2023.
  • 129 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2024.

Based on Virtu Financial's 13F filing for Q1 2024, filed 20 May 2024.